Description
FEMOSTON 1/10MG TABLETS 84S DESCRIPTION.
FEMOSTON 1/10MG TABLETS 84S, containing Estradiol and Dydrogesterone, constitute a Hormone Replacement Therapy (HRT) tailored for postmenopausal women. This medication, designed to alleviate symptoms postmenopause and prevent osteoporosis, integrates two essential female hormones: Oestrogen (Estradiol) and Progestogen (Dydrogesterone).
Femoston is prescribed to address the following conditions:
1. Menopause Symptoms: Menopause triggers a reduction in the production of oestrogen, leading to discomforting symptoms like hot flushes. Femoston effectively relieves these symptoms, particularly if they significantly disrupt daily life.
2. Osteoporosis Prevention: Postmenopausal women are susceptible to osteoporosis, characterized by weakened bones. Femoston serves as a preventive measure against osteoporosis, especially when other treatment options are unsuitable.
Estradiol, a form of oestrogen, mirrors the hormone naturally produced by ovaries before menopause. Similarly, Dydrogesterone, categorized as a progestogen, emulates the function of progesterone produced by ovaries pre-menopause.
Menopause typically occurs between ages 45 and 55, bringing about symptoms such as hot flushes, sleep disturbances, mood swings, and sexual discomfort due to vaginal dryness. Osteoporosis, characterized by bone weakening, is another common postmenopausal concern, elevating the risk of fractures, particularly in wrist, hip, and spine bones.
As part of HRT, women with uteruses require both oestrogen and progestogen to counteract the growth of the uterine lining induced by oestrogen alone. Dydrogesterone, as a progestogen component in Femoston, mitigates the risk of endometrial hyperplasia and irregular bleeding associated with oestrogen-only HRT post-menopause.
